PATENT CLAIM ANALYSIS

Application Number: 16267590
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["514", "396000"]

Abstract:
The present invention is directed to: a) a method of treating telangiectasia; b) a method of treating inflammatory lesions; and c) a method of treating two or more symptoms of rosacea selected from erythema, telangiectasia, or inflammatory lesions comprising topical administration of a pharmaceutical composition comprising oxymetazoline and a pharmaceutically acceptable excipient.

Claim (Index 45):
The method of  claim 21 , wherein the pharmaceutical composition further comprises an antioxidant selected from the group consisting of vitamin B, nordihydroguaiaretic acid, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate, erythorbate acid, sodium erythorbate, ascorbir palmitate, and ascorbir stearate, and a combination thereof.

Metadata:
- Claim Count in Document: 98.0
- Percentile: 99.0
- Lexical Diversity: 1.60526
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13309403', '14737360', '15984918', '15429873', '14209927']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.832492643738657
- 35 USC 102 Novelty (BERT): 0.5923248870993152
- Combined Prediction Score: 0.8084758680747227
- Mean Citation Score: 397.863074
- Max Citation Score: 606.4654
- Similarity Product: 413.9779581074597

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test